Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    25C-NBOMe molecular structure

    25C-NBOMe Stats & Data

    25c 2c-nbome Cimbi-82 2c-c-nbome Nbome-2c-c
    NPS DataHub
    MW335.83
    FormulaC18H22ClNO3
    CAS1227608-02-7
    IUPAC2-(4-chloro-2,5-dimethoxyphenyl)-~{N}-[(2-methoxyphenyl)methyl]ethanamine
    SMILESCOc1ccccc1CNCCc1cc(OC)c(Cl)cc1OC
    InChIKeyFJFPOGCVVLUYAQ-UHFFFAOYSA-N
    Phenethylamines
    Chemical Class N-benzylphenethylamine
    Psychoactive Class Psychedelic

    History & Culture

    25C-NBOMe was discovered in 2003 by Ralf Heim at the Free University of Berlin. The compound was subsequently investigated by a research team at Purdue University led by David Nichols, and was first formally described in the scientific literature by Anders Ettrup and colleagues in 2010. Research interest in 25C-NBOMe has centered on its potential applications in neuroimaging. Scientists have studied its carbon-11 radiolabelled form as a ligand for mapping the distribution of serotonin 5-HT2A receptors in the brain using positron emission tomography (PET). The compound had virtually no history of recreational human use prior to 2010, when it first emerged on the online research chemical market. Its exceptional potency—approximately sixteen times that of its parent compound 2C-C—allows effective doses to fit onto blotter paper, similar to LSD. This characteristic has led to instances where 25C-NBOMe has been found on blotter mimics sold as LSD, contributing to safety concerns and prompting regulatory responses across numerous jurisdictions beginning in 2011.

    Subjective Effects

    Physical

    The physical effects of 25C-NBOMe can be broken down into several components which progressively intensify proportional to dosage.

    • Stimulation and Sedation: In terms of its effects on the subject's physical energy levels, 25C-NBOMe is considered to be energetic and well as sedating, leaving the subject in a state of equilibrium between being stationary and moving. The physical stimulation manifested by this substance can be described as similar to 2C-B, and is commonly experienced as simultaneously easygoing and physically difficult, sometimes presenting overstimulation which results in bodily shakes and teeth grinding. The levels of stimulation can be considered less intense than 25I-NBOMe and the sedation can be considered slightly less intense than other psychedelics such as Psilocin and 2C-C.
    • Sublingual numbing: Assuming the substance has been taken sublingually, the very first physical effect which a person will notice immediately after sublingual absorption is a strong, unpleasant metallic chemical taste. This is accompanied by a very obvious feeling of general numbness of the tongue and mouth which can stay for up to an hour after the blotter paper has been consumed. This is the key difference when it comes to determining whether your blotter paper contains LSD or one of the NBOMe series.
    • Temperature regulation loss
    • Spontaneous tactile sensations: The body high itself can be described as a generally mild, all-encompassing, soft but euphoric tingling sensation. This tingling sensation is also accompanied by spontaneous rushes of euphoria that become longer and more drawn out proportional to the dosage consumed.
    • Perception of decreased weight: In terms of the body's perceived weight, this substance consistently leaves people feeling extremely light, often to the point of total weightlessness.
    • Tactile hallucinations
    • Changes in gravity: Compared to classic tryptamines, this effect is considerably less intense than what is commonly experienced with DMT and Psilocin.
    • Nausea: As the tripper begins to come up, nausea is not uncommon and can sometimes result in initial vomiting, but passes once this has either happened or the trip begins to fully set in. In comparison to other psychedelics such as psilocin, LSD, 2C-E and 2C-I, this could actually be very considered very mild in its intensity.
    • Vasoconstriction
    • Increased heart rate
    • Pupil dilation
    • Wakefulness
    • Increased blood pressure
    Cognitive

    The cognitive effects of 25C-NBOMe are described by many as remarkably light and underwhelming in comparison to more traditional psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages, however, mild to overwhelming cognitive alterations become present; this dosage seems to be lower in proportion to physical effects when compared to 25I-NBOMe.

    • Analysis enhancement: This component is consistently manifested only in the context of a non-social setting in which the user is alone and is introspection dominant.
    • Empathy, love and sociability enhancement: The entactogenic effects range from mild to powerful, but are inconsistently manifested. Entactogenic effects for people who try this substance usually become prominent in the presence of others. These feelings of increased sociability, love and empathy do not seem to be quite as strong or profound as those found within other entactogens (such as MDMA, 2C-B and AMT)
    • Thought acceleration
    • Time distortion
    • Immersion enhancement
    • Novelty enhancement
    • Conceptual thinking
    • Thought connectivity
    • Current mind state enhancement
    • Personal bias suppression
    • Memory suppression
    • Ego death
    Sensory
    Auditory
    • Enhancements
    • Distortions
    • Hallucinations
    Visual · Distortions
    • Drifting: (Melting, flowing, breathing and morphing) - In comparison to other psychedelics this effect can be described as highly detailed, slow and smooth in motion, static in their appearance and unrealistic/cartoon-like in style.
    • Tracers
    • After images
    • Symmetrical texture repetition
    • Colour shifting
    • Scenery slicing
    • Transformations
    • Environmental cubism
    • Diffraction
    Visual · Enhancements

    25C-NBOMe presents a full and complete array of possible visual enhancements.

    • Visual acuity enhancement
    • Colour enhancement
    • Pattern recognition enhancement
    Visual · Hallucinatory States

    25C-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently. However, level 4 - 5 hallucinatory breakthroughs are reported but very uncommon and inconsistent in comparison to other more commonly used psychedelics such as psilocin, 2C-E and DMT. This can be considered as on par with and identical in behaviour to that of LSD and 25I-NBOMe.

    • Transformations
    • Internal hallucinations: (Autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots) These are more common within dark environments and can be described as internal in their manifestation, lucid in believability, interactive in style and almost exclusively of religious, spiritual, mystical or a transcendental nature in their overall theme.
    • External hallucinations: (Autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots). These are often manifesting as rapidly moving, interactive solid and typically asymmetrical matter or physical beings reflecting imagined concepts. They are more common in bright environments and can be described as external in their manifestation, equally lucid and delirious in believability, interactive in style, autonomous in interaction, and almost exclusively alien, mystical, or a transcendental nature in their overall theme.

    Forked from Subjective Effect Documentation by Josie Kins, September 2015. Via dose.wiki (CC0).

    Toxicity

    PsychonautWiki

    25C-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The LD50 has not yet been determined although it can be fatal at heavy dosages. It is advised that due to 25C-NBOMe's extreme potency it should not be insufflated (snorted) as this method of administration has been attributed to several fatal overdoses due to improper dosing. It is strongly recommended that one use harm reduction practices when using this substance.

    Addiction & dependence

    25C-NBOMe is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating. Tolerance to the effects of 25C-NBOMe is built almost immediately after ingestion.

    Effect Profile

    Curated + 83 Reports
    Psychedelic 8.8

    Strong visuals, headspace, and auditory effects with strong body load

    Visual Intensity×3
    10103.0
    Headspace Depth×3
    108.12.2
    Auditory Effects×1
    10102.2
    Body Load / Somatic Effects×1
    108.25.2
    Catalog Erowid BlueLight

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Sublingual
    0-12 minutes
    30 minutes - 1.5 hours
    4-6 hours
    1-4 hours
    1-24 hours
    Total: 8-10 hours
    Insufflated
    45-90 minutes hours
    1-24 hours
    Total: 5-8 hours

    Community Effects

    TripSit
    Positive
    visual enhancement creativity
    Negative
    nausea vomiting body load

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    Psilocybin
    Psilocin
    Mescaline
    DMT
    5-MeO-DMT
    2C-B
    2C-E

    Experience Report Analysis

    Erowid BlueLight
    113 Reports
    60 Single-substance
    2010–2015 Date Range
    107 With Age Data
    31 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 83 experience reports (60 single-substance Erowid + 23 Bluelight)

    83 Reports
    105 Effects Detected
    42 Positive
    44 Adverse
    19 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Positive Effects 42

    Visual Distortions 66.2% (95% interval 56 to 76 percent) 65%
    Music Enhancement 46.7% (95% interval 35 to 59 percent) 70%
    Color Enhancement 45.8% (95% interval 36 to 56 percent) 86%
    Euphoria 41.0% (95% interval 31 to 52 percent) 88%
    Stimulation 31.3% (95% interval 22 to 42 percent) 82%
    Surface Breathing 30.4% (95% interval 16 to 51 percent) 82%
    Empathy 25.3% (95% interval 17 to 36 percent) 85%
    Closed-Eye Visuals 21.7% (95% interval 14 to 32 percent) 83%
    Visual Trails 21.7% (95% interval 10 to 42 percent) 86%
    Introspection 20.5% (95% interval 13 to 30 percent) 80%
    Body High 19.2% (95% interval 12 to 29 percent) 85%
    Geometric Imagery 17.4% (95% interval 7 to 37 percent) 84%
    Contentment 17.4% (95% interval 7 to 37 percent) 79%
    Tingling 17.4% (95% interval 7 to 37 percent) 86%
    Patterning 17.4% (95% interval 7 to 37 percent) 89%
    Tactile Enhancement 16.9% (95% interval 10 to 26 percent) 81%
    Open-Eye Visuals 15.7% (95% interval 9 to 25 percent) 82%
    Pain Relief 15.0% (95% interval 8 to 26 percent) 70%
    Clarity 13.0% (95% interval 4 to 32 percent) 82%
    Focus Enhancement 9.6% (95% interval 5 to 18 percent) 78%

    Adverse Effects 44

    Anxiety 50.6% (95% interval 40 to 61 percent) 87%
    Body Load 30.4% (95% interval 16 to 51 percent) 80%
    Fear 26.1% (95% interval 12 to 46 percent) 90%
    Thought Disorganization 26.1% (95% interval 12 to 46 percent) 81%
    Confusion 21.7% (95% interval 14 to 32 percent) 82%
    Nausea 21.7% (95% interval 14 to 32 percent) 85%
    Tremor 21.7% (95% interval 10 to 42 percent) 77%
    Body Temperature Change 21.7% (95% interval 10 to 42 percent) 81%
    Muscle Tension 13.3% (95% interval 8 to 22 percent) 85%
    Increased Heart Rate 13.3% (95% interval 7 to 24 percent) 70%
    Pupil Dilation 13.2% (95% interval 8 to 22 percent) 88%
    Insomnia 13.0% (95% interval 4 to 32 percent) 83%
    Paranoia 13.0% (95% interval 4 to 32 percent) 87%
    Panic 13.0% (95% interval 4 to 32 percent) 95%
    Headache 12.0% (95% interval 7 to 21 percent) 82%
    Jaw Clenching 9.6% (95% interval 5 to 18 percent) 82%
    Paranoid Ideation 8.7% (95% interval 2 to 27 percent) 90%
    Restlessness 8.7% (95% interval 2 to 27 percent) 78%
    Warping 8.7% (95% interval 2 to 27 percent) 85%
    Delusion 8.7% (95% interval 2 to 27 percent) 90%
    ⚠ Seizure 5.0% (95% interval 2 to 14 percent) 70%
    Show 23 more adverse effects
    Dysphoria 8.7% (95% interval 2 to 27 percent) 90%
    Muscle Spasm 8.7% (95% interval 2 to 27 percent) 78%
    Motor Suppression 8.7% (95% interval 2 to 27 percent) 75%
    Dizziness 8.7% (95% interval 2 to 27 percent) 80%
    Amnesia 8.7% (95% interval 2 to 27 percent) 88%
    Memory Suppression 8.4% (95% interval 4 to 16 percent) 90%
    Sweating 8.4% (95% interval 4 to 16 percent) 75%
    Thought Loops 8.4% (95% interval 4 to 16 percent) 90%
    Depersonalization 4.3% (95% interval 1 to 21 percent) 85%
    Embarrassment 4.3% (95% interval 1 to 21 percent) 80%
    Sadness 4.3% (95% interval 1 to 21 percent) 80%
    Urinary Retention 4.3% (95% interval 1 to 21 percent) 75%
    Focus Suppression 4.3% (95% interval 1 to 21 percent) 75%
    Social Anxiety 4.3% (95% interval 1 to 21 percent) 85%
    Body Distortion 4.3% (95% interval 1 to 21 percent) 85%
    Distance Distortion 4.3% (95% interval 1 to 21 percent) 90%
    Out-Of-Body Experience 4.3% (95% interval 1 to 21 percent) 85%
    Melting/flowing 4.3% (95% interval 1 to 21 percent) 85%
    Identity Confusion 4.3% (95% interval 1 to 21 percent) 85%
    Irritability 4.3% (95% interval 1 to 21 percent) 75%
    Pressure 4.3% (95% interval 1 to 21 percent) 75%
    Tension 4.3% (95% interval 1 to 21 percent) 80%
    Cold Flashes 4.3% (95% interval 1 to 21 percent) 80%
    Show 19 neutral or unclassified mentions
    Time Dilation 26.1% (95% interval 12 to 46 percent)
    Auditory Effects 25.3% (95% interval 17 to 36 percent)
    Dissociation 16.7% (95% interval 9 to 28 percent)
    Sedation 15.7% (95% interval 9 to 25 percent)
    Hospital 15.0% (95% interval 8 to 26 percent)
    Ego Dissolution 12.0% (95% interval 7 to 21 percent)
    Dry Mouth 8.7% (95% interval 2 to 27 percent)
    Numbness 8.7% (95% interval 2 to 27 percent)
    Appetite Suppression 8.7% (95% interval 2 to 27 percent)
    Communication Suppression 8.7% (95% interval 2 to 27 percent)
    Entity Imagery 8.7% (95% interval 2 to 27 percent)
    Time Distortion 7.2% (95% interval 3 to 15 percent)
    Depth Distortion 4.3% (95% interval 1 to 21 percent)
    Balance Change 4.3% (95% interval 1 to 21 percent)
    Temperature Dysregulation 4.3% (95% interval 1 to 21 percent)
    Teeth Grinding 4.3% (95% interval 1 to 21 percent)
    Frequent Urination 4.3% (95% interval 1 to 21 percent)
    Language Distortion 4.3% (95% interval 1 to 21 percent)
    Chills 4.3% (95% interval 1 to 21 percent)

    Also reported in combinations. In the 53 25C-NBOMe reports where another drug was taken too, 7 (13.2%) mention hospital, emergency services or an overdose, 2 (3.8%) a seizure and 5 (9.4%) psychosis. In the 60 single-substance reports: 15.0%, 5.0% and 0.0%. These are not in the figures above: they cannot be put down to 25C-NBOMe alone, and a mention is not always something that happened to the writer.

    Dose-Response Correlation

    How effect frequency changes across dose levels. Whiskers, and the numbers' hover text, give each figure's 95% interval.

    Not drawn, too few reports (a dose tier needs 20): Sublingual Common (n=14). Why 20?

    Subjective Effect Ontology

    Experience Reports

    Structured effect tags extracted from 136 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.

    Visual

    visual distortions 108 79.4% (95% interval 72 to 85 percent)

    1 unique effects extracted · Derived from Erowid & Bluelight reports

    Dosage Distribution

    Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

    Sublingual

    Median: 500.0 µg IQR: 300.0–562.5 µg n=15

    Insufflated

    Median: 550.0 µg IQR: 425.0–950.0 µg n=14

    1 dose more than 50 times the median may be a typing or unit error and is not in the figures either: check the report.

    Show the report

    Possibly a typing or unit error:

    Real-World Dose Distribution

    Erowid

    From 83 of 125 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

    Sublingual (n=48)

    Median: 0.51mg 25th: 0.38mg 75th: 0.93mg 90th: 1.0mg

    Insufflated (n=21)

    Median: 0.4mg 25th: 0.25mg 75th: 0.6mg 90th: 1.3mg

    Oral (n=10)

    Median: 0.9mg 25th: 0.62mg 75th: 1.38mg 90th: 1.55mg

    Common Combinations

    Most co-occurring substances, as a share of all 113 reports filed under 25C-NBOMe; whiskers are 95% intervals

    Form / Preparation

    Most common forms and preparations, as a share of the 99 reports that give one; whiskers are 95% intervals

    Body-Weight Dosing

    Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

    Sublingual

    Median: 0.006 mg/kg IQR: 0.004–0.007 mg/kg n=14

    Unknown

    Median: 0.01 mg/kg IQR: 0.006–0.014 mg/kg n=17

    Insufflated

    Median: 0.007 mg/kg IQR: 0.005–0.013 mg/kg n=14

    1 dose more than 50 times the median may be a typing or unit error and is not in the figures either: check the report.

    Show the report

    Possibly a typing or unit error:

    Oral

    Median: 0.02 mg/kg IQR: 0.012–0.032 mg/kg n=6

    Redose Patterns

    Redosing behavior across 100 reports

    14.0% (95% interval 8 to 22 percent) Redosed
    1.2 Avg Doses
    180m Median Interval

    Legal Status

    Country Status Notes
    Austria Illegal (SMG) Prohibited since June 26, 2019 under the Suchtmittelgesetz (SMG). Possession, production, and sale are illegal.
    Brazil Controlled Listed on Portaria SVS/MS nº 344 as of February 18, 2014. The entire NBOMe series became controlled at this time, including 25I-, 25C-, 25D-, 25B-, 25E-, 25N-, 25P-, 25T2-, 25T7-, and 25H-NBOMe.
    Canada Schedule III (CDSA) Controlled as of October 31, 2016 as a derivative of 2,5-dimethoxyphenethylamine under the Controlled Drugs and Substances Act.
    China Controlled Classified as a controlled substance since October 2015.
    Czech Republic Banned Prohibited under national controlled substances legislation.
    Germany Anlage I BtMG Listed in Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since December 13, 2014. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license are prohibited.
    Israel Controlled The NBOMe series became controlled in May 2013.
    Italy Schedule I Classified as a Schedule I controlled substance. Possession, distribution, and manufacture are illegal.
    Japan Narcotic Designated as a narcotic drug effective November 1, 2015.
    Latvia Schedule I Classified as a Schedule I controlled substance.
    New Zealand Class C analogue Considered substantially similar in chemical structure to the controlled hallucinogen DOB and therefore treated as a Class C controlled drug analogue. Withdrawn from sale in early 2012 following a statement by Associate Health Minister Peter Dunne.
    Russia Controlled The entire NBOMe series became controlled in October 2011, making Russia the first country to regulate this class of substances.
    Sweden Schedule I Added to Schedule I (substances without medical use) as of August 1, 2013, published in Medical Products Agency regulation LVFS 2013:15.
    Switzerland Controlled (Verzeichnis D) Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics legislation.
    Turkey Illegal Classified as a controlled drug. Possession, production, supply, and import are prohibited.
    United Kingdom Class A Controlled as a Class A substance since June 2014 under the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971. Previously subject to a temporary class drug order from June 10, 2013.
    United States Schedule I Emergency scheduled by the DEA on November 15, 2013, along with 25B-NBOMe and 25I-NBOMe under the Controlled Substances Act. The temporary scheduling was extended in November 2015. Several states including Arkansas, Georgia, and Louisiana added it to their Schedule I lists prior to federal action. Scheduling also makes other NBOMe compounds probable Controlled Substance Analogues when intended for human consumption.
    ← Back to 25C-NBOMe